Blueprint vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical measurement and therapy outcomes platform for mental health providers, Austin TX, raised $8M+. Automates outcome tracking and progress notes for therapists.
About
Blueprint is an Austin, Texas-based clinical technology company founded in 2018 that provides mental health providers with a measurement-based care platform designed to automate outcomes tracking, streamline progress note documentation, and improve the quality and consistency of mental health treatment. The company has raised over $8 million and serves thousands of therapists and group practices seeking to implement structured clinical measurement without significant workflow disruption.\n\nBlueprint's platform automates the collection of validated clinical questionnaires (such as PHQ-9, GAD-7, and PCL-5) before or between sessions, presents clinicians with outcome trend visualizations at the point of care, and generates draft progress notes based on session data. The AI-assisted note generation feature is particularly valued by clinicians who spend significant time on documentation after sessions, with Blueprint reducing note completion time while improving clinical documentation quality and compliance.\n\nThe company distributes through direct sales to individual therapists and group practices, and is expanding partnerships with group practice management platforms and EHR vendors to embed its measurement capabilities into existing clinical workflows. Blueprint competes with Greenspace Health and Osmind in the measurement-based care space, and with Nabla and Heidi Health in the AI-assisted clinical documentation market. The intersection of outcomes accountability and administrative relief positions Blueprint as both a quality improvement tool and a therapist burnout reduction solution.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.